fda pulls tirzepatide ๐จ Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these FDA is moving to restrict
Description
This will only apply if the patient sends a written notice via email to [email protected] within 24 hours from the time the provider-led health review was completed
Hector Perez, MD, a board certified bariatric surgeon at Renew Bariatrics and an advisor at BestSurgeons.com, who was not involved in the study, said that while the risk for ION is worth monitoring, the study is very small

Example: 75 units divided by 100 equals 0.75 mL

Customised dosing: The compounded nature allows for tailored strength and individualisation depending on the patients response and tolerability

PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you
